Hematology (all articles)
Observational study: Among patients hospitalized with Covid-19 not receiving mechanical ventilation, transfusion of plasma with higher anti–SARS-CoV-2 IgG antibody levels is linked to lower risk of death than transfusion of plasma with lower antibody levels
15 Jan, 2021 | 08:59h | UTCEditorial: (A Little) Clarity on Convalescent Plasma for Covid-19 – New England Journal of Medicine
Commentaries: Expert reaction to study looking at convalescent plasma antibody levels and risk of death from COVID-19 – Science Media Centre AND Antibody-rich convalescent plasma may lower risk of COVID death – CIDRAP
Opinion: RCTs don’t justify using convalescent plasma or antibody cocktails
15 Jan, 2021 | 08:58h | UTCRCTs don’t justify using convalescent plasma or antibody cocktails – PulmCrit
Randomized trial: Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma
15 Jan, 2021 | 08:12h | UTCOnce-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Commentary: Triplet therapy slows refractory multiple myeloma – MedicalXpress
Systematic review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
13 Jan, 2021 | 01:37h | UTC
Blood plasma treatment has limited effect for sickest COVID-19 patients
12 Jan, 2021 | 02:07h | UTCBlood plasma treatment has limited effect for sickest COVID-19 patients – Imperial College London
See also: Expert reaction to REMAP-CAP recruitment of severely ill COVID-19 patients into convalescent plasma trial being paused after initial analysis suggested it did not improve outcomes – Science Media Centre AND Trial of COVID-19 blood plasma finds no benefit in severely ill patients – Reuters
Randomized trial: Plasma therapy administered early is beneficial in high-risk elderly patients
12 Jan, 2021 | 02:05h | UTCCommentaries: Early convalescent plasma may lower risk of severe COVID in seniors – CIDRAP AND Covid-19: Early Plasma Treatment Improved Outcomes in Older Patients – Physician’s Weekly
Commentaries on Twitter
Just published @NEJM: A small, placebo-controlled randomized trial (N=160) of high IgG titer convalescent plasma administered early (within 72 hrs) for mild covid-19 to older adults (median age >70) shows benefit https://t.co/dhyFH4OwpH pic.twitter.com/14lMBBofUh
— Eric Topol (@EricTopol) January 6, 2021
Early convalescent plasma may lower risk of severe COVID in seniors@NEJM study finds that 16% of those treated with high-titer convalescent therapy developed severe #COVID19, compared with 31% in the placebo grouphttps://t.co/7hqCXsNHDM pic.twitter.com/dZDUwcjxUh
— CIDRAP (@CIDRAP) January 6, 2021
ACC Consensus: Anticoagulation and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing PCI or with atherosclerotic cardiovascular disease
12 Jan, 2021 | 01:50h | UTCCommentaries: ACC Issues New Guidance Around Antithrombotic Choices in A-fib, VTE – TCTMD AND ACC Issues Clinical Guidance For Antithrombotic Therapy in Patients With AFib or VTE Undergoing PCI or With ASCVD – American College of Cardiology
Commentary on Twitter
ICYMI: @ACCinTouch released clinical guidance for antithrombotic therapy in pts w/ #AFib/#VTE undergoing PCI or w/ #ASCVD. Doc aims to serve as a framework for decision-making among pts requiring concomitant use of an anticoagulant & antiplatelet therapy. https://t.co/PqinRIvLY9 pic.twitter.com/prbnbBPG5L
— JACC Journals (@JACCJournals) December 29, 2020
[Press release – results not published yet] International trials of blood thinners in critically ill COVID-19 patients pause due to futility
10 Jan, 2021 | 20:44h | UTC
Commentary on Twitter
The 3 largest RCTs of therapeutic #anticoagulation for #COVID19 pts in the ICU have ALL been stopped early for futility. (@remap_cap @ATTACC_COVID & #ACTIV4)
Nothing published yet, but given the large n of these RCTs, I'm increasingly skeptical about anticoagulation in COVID19. pic.twitter.com/RrLSoOsp3v
— Nick Mark MD (@nickmmark) December 22, 2020
Randomized trial: In extremely-low-birth-weight infants, a higher hemoglobin threshold for red-cell transfusion does not improve outcomes
10 Jan, 2021 | 20:36h | UTCHigher or Lower Hemoglobin Transfusion Thresholds for Preterm Infants – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Higher red cell transfusion threshold offers no advantage for treating preterm infants – NIH News Releases
Case series: Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer
2 Dec, 2020 | 07:31h | UTC
NICE COVID-19 guideline: Prevention of thromboembolism in patients with COVID-19. “For patients who are having advanced respiratory support: consider increasing pharmacological VTE prophylaxis to an intermediate dose”
1 Dec, 2020 | 08:19h | UTC
Randomized trial: Intravenous iron is superior to oral iron for the treatment of anemia in women after childbirth in a low-income setting
27 Nov, 2020 | 08:41h | UTC
Commentary on Twitter
In a randomised trial in Tanzania, intravenous ferric carboxymaltose proved safe and better than oral iron at achieving haemoglobin normalisation (>115 g/L) at 6 weeks after childbirth in women with iron deficiency anaemia https://t.co/F5sau45dwL pic.twitter.com/qqa8cGbMqZ
— The Lancet Global Health (@LancetGH) November 25, 2020
Randomized trial: Convalescent Plasma does not improve clinical status or overall mortality in severe Covid-19 pneumonia
25 Nov, 2020 | 09:17h | UTCCommentary: New trial of convalescent plasma for covid-19 falls flat, another setback for hyped treatment – Brief19
Commentary on Twitter
A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia @NEJM A well conducted RCT shows no significant differences in clinical status or overall mortality between patients treated with CP and those who received placebo. https://t.co/C6NylbO2At
— Carlos del Rio (@CarlosdelRio7) November 24, 2020
Diagnosis, management, and pathophysiology of arterial and venous thrombosis in COVID-19
24 Nov, 2020 | 09:34h | UTCDiagnosis, Management, and Pathophysiology of Arterial and Venous Thrombosis in COVID-19 – JAMA
Commentary on Twitter
Arterial and venous thrombosis are common in #COVID19, especially in critically ill patients. Thromboprophylaxis should be considered for all hospitalized patients with COVID-19 in the absence of contraindications https://t.co/sjqL7MqGLX
— JAMA (@JAMA_current) November 23, 2020
Treatment of community-acquired pneumonia in immunocompromised adults: A consensus statement regarding initial strategies
17 Nov, 2020 | 09:40h | UTCEditorial: Management of Community-Acquired Pneumonia in Immunocompromised Adults – CHEST
#AHA20 – In patients hospitalized for heart failure with iron deficiency, intravenous Ferric carboxymaltose at discharge reduced the risk of heart failure rehospitalizations
16 Nov, 2020 | 01:53h | UTCCommentaries: Intravenous iron reduced rehospitalization risk in people with heart failure – American Heart Association AND AFFIRM-AHF: IV Iron Supplementation Linked to Fewer Repeat Hospitalizations for HF – TCTMD
Commentary on Twitter
Latebreaker at #AHA20 @AHAMeetings—Ferric carboxymaltose for iron deficiency at discharge after acute #heartfailure: AFFIRM-AHF, a multicentre, double-blind, randomised, controlled trial https://t.co/gRKtbsxfba pic.twitter.com/k67HDJMW2b
— The Lancet (@TheLancet) November 14, 2020
Review: Diagnosis and treatment of lower extremity venous thromboembolism. Role of pretest probability and D-Dimer on diagnosis + treatment issues such as postthrombotic syndrome and the role of new anticoagulants
5 Nov, 2020 | 09:00h | UTCDiagnosis and Treatment of Lower Extremity Venous Thromboembolism: A Review – JAMA (free for a limited period)
Summary: Diagnosis and Treatment of Lower Extremity Venous Thromboembolism – American College of Cardiology
Randomized trial: Vitamin C does not improve iron absorption in adult patients with iron deficiency anemia
4 Nov, 2020 | 09:42h | UTCCommentary: Study: Vitamin C Supplements Have No Effect on Iron-Deficiency Anemia – NEJM Journal Watch
Commentary on Twitter
RCT finds oral iron alone is equivalent to oral iron + #vitaminC in improving hemoglobin and iron absorption in patients with iron deficiency #anemia https://t.co/atSVVnGkEV #VisualAbstract
— JAMA Network Open (@JAMANetworkOpen) November 2, 2020
Systematic review: Antithrombotic drugs for people with antiphospholipid syndrome
28 Oct, 2020 | 08:50h | UTC
Randomized trial: Convalescent plasma ineffective for patients hospitalized with Covid-19
23 Oct, 2020 | 09:15h | UTCEditorial: Convalescent plasma is ineffective for covid-19 – The BMJ
Commentary on Twitter
Just published @bmj_latest: A randomized trial of convalescent plasma for moderate covidhttps://t.co/dUvEMFSLHG
No benefit. It was underpowered to detect mortality reduction with 464 patients. A large RCT is needed to resolve the question, but these findings are not encouraging. pic.twitter.com/WGtz9IVSZe— Eric Topol (@EricTopol) October 23, 2020
Pro/con debate: Therapeutic anticoagulation in hospitalized patients with Covid-19 without established thromboembolism
23 Oct, 2020 | 09:12h | UTCAnticoagulation in Hospitalized Patients with Covid-19 – New England Journal of Medicine
Related editorial: Anticoagulation in COVID-19: It Is Time for High-Quality Evidence – Journal of the American College of Cardiology
Podcast: Deep vein thrombosis and pulmonary embolism
23 Oct, 2020 | 08:58h | UTC#238 DVT / PE Triple Distilled – The Curbsiders Internal Medicine Podcast
Position Statement: Standardizing care to manage bleeding disorders in adolescents with heavy menses
21 Oct, 2020 | 09:07h | UTC
Meta-analysis: The association of D-dimers with mortality, intensive care unit admission or ARDS in patients hospitalized with COVID-19
20 Oct, 2020 | 01:37h | UTC
New studies show reduced prevalence and severity of SARS-CoV-2 infection in ABO blood group O
18 Oct, 2020 | 23:16h | UTCStudy 1: Reduced prevalence of SARS-CoV-2 infection in ABO blood group O – Blood Advances
Commentaries: People with blood type O may have lower risk of Covid-19 infection and severe illness, two new studies suggest – CNN AND Studies offer new evidence for possible link between blood type and COVID-19 susceptibility – American Society of Hematology